RCT | Letermovir demonstrates noninferiority to valganciclovir for CMV prophylaxis in kidney transplantation

Letermovir vs Valganciclovir for Prophylaxis of Cytomegalovirus in High-Risk Kidney Transplant Recipients: A Randomized Clinical Trial – JAMA (free for a limited period)

Editorial: A New Antiviral Option for Cytomegalovirus Prevention After Kidney Transplant – JAMA (free for a limited period)

See also: Visual Abstract

Commentary: Newly approved antiviral is promising alternative against cytomegalovirus illness in kidney transplants – CIDRAP